SCHEMBL688927

SCHEMBL688927

CN1CCC1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3419839 1.00
SCHEMBL805210 1.00
SCHEMBL27661980 0.86 ACE (0.33)
SCHEMBL145545 0.85
SCHEMBL163401 0.85
SCHEMBL77336 0.85
Hydrochloric Acid SCHEMBL113878 0.83 ACE (0.46)
Water SCHEMBL1598131 0.83 ACE (0.46)
Hydrochloric Acid SCHEMBL1721046 0.83 ACE (0.46)
SCHEMBL2737878 0.83 ACE (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099843-A1 DOLASTATIN 15 DERIVATIVES ABBOTT GMBH & CO. KG (DE) 2010-04-22 US claimed
CN-119855820-A Camptothecins compound and its preparation method and use 上海齐鲁制药研究中心有限公司 2025-04-18 CN disclosed
US-20250084087-A1 BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS INCYTE CORPORATION 2025-03-13 US disclosed
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
WO-2024125627-A1 CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海齐鲁制药研究中心有限公司 2024-06-20 WO disclosed
EP-3647311-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-11-01 EP disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230122651-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2023-04-20 US disclosed
EP-1363631-A2 COMPOUNDS USEFUL AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Bristol-Myers Squibb Company (US) 2003-11-26 EP disclosed
US-20030092732-A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2003-05-15 US disclosed
US-20030069169-A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders BRISTOL-MYERS SQUIBB COMPANY 2003-04-10 US disclosed
WO-2002079146-A2 COMPOUNDS USEFUL AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-10 WO disclosed
US-6458765-B1 POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION BASF AKTIENGESELLSCHAFT (DE) 2002-10-01 US disclosed
WO-2002069905-A2 CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-09-12 WO disclosed
US-6143721-A FOR TREATING CANCER IN MAMMALS BASF AKTIENGESELLSCHAFT (DE) 2000-11-07 US disclosed
CN-1264388-A Dolastatin 15 derivatives ABSF AG (DE) 2000-08-23 CN disclosed
EP-0991658-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-04-12 EP disclosed
WO-1999003879-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1999-01-28 WO disclosed